Linezolid Krka (Linezolid)

Linezolid is an oxazolidinone antibacterial indicated for serious Gram‑positive infections.

• Methicillin‑resistant Staphylococcus aureus (MRSA) infections: effective treatment of skin, bloodstream or respiratory infections caused by MRSA.
• Vancomycin‑resistant Enterococcus (VRE) infections: provides an alternative option for infections unresponsive to vancomycin.
• Community‑acquired and hospital‑acquired pneumonia: helps resolve pneumonia caused by susceptible Gram‑positive pathogens.
• Skin and soft‑tissue infections: treats cellulitis, abscesses and other soft‑tissue infections due to resistant Gram‑positive bacteria.

• Linezolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing formation of the initiation complex required for translation. This action blocks the early stage of peptide chain assembly, leading to a bacteriostatic effect against susceptible Gram‑positive organisms, including strains resistant to other classes. By targeting a site distinct from that of macrolides, lincosamides or chloramphenicol, linezolid retains activity where those agents fail, and it does not affect human mitochondrial ribosomes at therapeutic concentrations.

Linezolid may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Headache: transient cranial discomfort.
• Diarrhea: loose stools, usually self‑limited.
• Metallic taste: altered taste sensation during therapy.

Serious or Rare Side Effects

• Thrombocytopenia: significant reduction in platelet count, requiring monitoring.
• Peripheral neuropathy: sensory disturbances that may become irreversible with prolonged use.
• Serotonin syndrome: risk when combined with serotonergic agents, presenting with agitation, hyperreflexia and autonomic instability.

When prescribing Linezolid, clinicians should consider several safety measures.

• Renal or hepatic impairment: monitor liver function tests and adjust therapy if needed.
• Concomitant serotonergic drugs: avoid due to risk of serotonin syndrome.
• Prolonged therapy (>14 days): assess for hematologic abnormalities.
• Pregnancy and lactation: use only if benefits outweigh risks, as safety data are limited.
• Store at ambient temperature: keep below 25 °C, protect from moisture and light in original packaging.

Linezolid interacts with several drug classes that may alter its safety or efficacy.

Major Interactions (Avoid)

• Selective serotonin reuptake inhibitors (SSRIs) and other serotonergic agents: risk of serotonin syndrome.
• Monoamine oxidase inhibitors (MAOIs): increased risk of serotonin toxicity.
• Rifampin: reduces linezolid plasma concentrations, potentially compromising efficacy.

Moderate Interactions (Monitor Closely)

• Warfarin: may enhance anticoagulant effect; monitor INR regularly.
• Cytochrome P450 inducers (e.g., carbamazepine): may lower linezolid exposure.
• Antacids containing magnesium or aluminum: may affect absorption; separate administration by at least 2 hours.